danone glp 1 launches innovation for weight-loss medication users and natural appetite control. Oikos Protein Shake coming to

Market expansion is being supported by the growing recognition of obesity as a chronic disease requiring pharmacological intervention and the compelling clinical evidence demonstrating substantial cardiovascular risk reduction in treated populations

The obtained LOD and LOQ were 0.09 and 0.29 ng/g, respectively, demonstrating high sensitivity of the conversion SIDA method for CNCbl analysis

Whilst these findings were encouraging, the study was relatively small and designed primarily to assess safety and feasibility rather than definitive efficacy

Despite these gaps, GLP-1s are being prescribed more often to people with PWS

S., Cobbold, S